The Association Between Phenotypic Age and Primary Loss of Response to Biologic Agent in Patients with Crohn's Disease

克罗恩病患者表型年龄与生物制剂原发性疗效丧失之间的关联

阅读:1

Abstract

PURPOSE: Loss of response (LOR) to biological agents is challenging in Crohn's disease (CD) therapy. Identifying and predicting factors associated with therapeutic responses enables proactive intervention in high-risk LOR populations, such as adjusting therapeutic intensity or initiating second-line agents earlier, to avoid ineffective treatment and improve clinical outcomes. A few studies have also shown that biological age may be associated with treatment responses. This study aimed to show the association between phenotypic age, a type of biological age, and the primary loss of response to biological agents in patients with CD. METHODS: This retrospective study included 94 CD patients, with 81 followed-up at the eighth week and 76 at the twelfth week in our institution. LOR was defined as biochemical remission (fecal calprotectin level < 250 μg/g or a reduction of > 50% from baseline levels). The phenotypic age was calculated based on a series of clinical biomarkers. Multivariate regression analysis was used to determine the association between phenotypic age and the LOR. The receiver operating characteristic curve (ROC) was used to show the performance of biological age in predicting the 8-week and 12-week LOR. RESULTS: 33 patients had LOR at 8 weeks and 34 patients had LOR at 12 weeks. Patients with LOR had a higher phenotypic age and age gap than those with response (p < 0.001). Multivariable regression analyses further showed that phenotypic age and age gap were associated with LOR (8-week LOR, odds ratio (OR) = 1.18, 95% confidence interval (CI):1.07-1.32 and OR = 0.84, 0.76-0.94; 12-week LOR, OR = 1.12, 95% CI:1.02-1.24 and OR = 0.89, 95% CI:0.81-0.98). ROC curves showed that both phenotypic age and age gap had acceptable performance in predicting 8-week and 12-week LOR (the area under the curve (AUC) was 0.739-0.784). CONCLUSION: Phenotypic age is associated with LOR to biological agent in patients with CD, and has acceptable performance in predicting 8-week and 12-week LOR.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。